ADTX Aditxt Corp: רווח נקי למניה ב-12 החודשים האחרונים

Aditxt is undergoing a painful business model pivot as it strives to become an IT hub for medicine and reduce its debt. The EPS YoY TTM growth trajectory visualizes this process, where 100.20 serves as the base parameter value. Stability is driven by precision immunity tests in the US and optimized express delivery logistics for analysis, ensuring high margins across all operating cycles.

For Aditxt (ADTX), a leader in the immune monitoring niche, this indicator reflects the monetization efficiency of the AditxtScore platform. The metric measures the percentage change in net income per share over the last 12 months. Analysis of the EPS TTM annual trend chart reveals hidden rates of business deceleration. Inelastic demand for transplantation tests provides the company with pricing power. Stable profit growth confirms the fundamental resilience of the business model.